ストックスクリーナーアプリを入手
5.64
8.67%
0.45
アフターアワーズ：
5.64
前日終値:
$5.19
開ける：
$5.25
24時間の取引高:
984.10K
Relative Volume:
0.93
時価総額：
$233.48M
収益：
$134.48M
当期純損益:
$-38.94M
株価収益率:
-5.9157
EPS:
-0.9534
ネットキャッシュフロー:
$-19.34M
1週間 パフォーマンス:
+0.53%
1か月 パフォーマンス:
+5.22%
6か月 パフォーマンス:
-38.83%
1年 パフォーマンス:
-29.23%
1日の値動き範囲:
$5.25
$5.68
1週間の範囲:
$5.055
$5.68
52週間の値動き範囲:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Compare RXST vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
5.64 | 214.85M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | 開始されました | William Blair | Mkt Perform |
| 2025-07-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | ダウングレード | Jefferies | Buy → Hold |
| 2025-07-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-09 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-09 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 開始されました | Piper Sandler | Neutral |
| 2025-04-09 | ダウングレード | UBS | Buy → Neutral |
| 2025-04-04 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2025-04-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-12-20 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-10-29 | 開始されました | Jefferies | Buy |
| 2024-08-20 | 繰り返されました | Needham | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-05-07 | 繰り返されました | BTIG Research | Buy |
| 2023-12-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | 開始されました | Morgan Stanley | Overweight |
| 2023-04-13 | 開始されました | Oppenheimer | Outperform |
| 2022-12-12 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 開始されました | Needham | Buy |
すべてを表示
Rxsight Inc (RXST) 最新ニュース
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer - hrtoday.in
Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles - Glance by Eyes On Eyecare
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RxSight grants new CEO Aziz Mottiwala stock options for 571,286 shares at $5.19 each - Bitget
RxSight grants inducement stock options and RSU... - Pluang
New RxSight CEO's 2.31M RSU award vests over three years - Stock Titan
Rxsight Inc (RXST) Income Statement - TradingKey
RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut - Yahoo Finance
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Form 4 Rxsight Inc For: 24 July By Investing.com - Investing.com Nigeria
RxSight, Inc. (RXST) awards CEO 2,312,138 RSUs and 571,286 options - Stock Titan
Lost Money on RxSight, Inc. (RXST)? Urged to Join Class Action Before September 22, 2025Contact Levi & Korsinsky - The National Law Review
RXST|Rxsight Inc|Price:5.205|Chg%:-0.165 - TradingKey
Midday Stock Roundup: Shares of loanDepot up 7% - Orange County Business Journal
Rxsight Inc (RXST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rxsight Inc (RXST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RXST|Rxsight Inc|Price:5.155|Chg%:-0.215 - TradingKey
(RXST) Movement as an Input in Quant Signal Sets - Stock Traders Daily
RxSight Lands Tarsus Commercial Leader as CEO - Orange County Business Journal
RxSight (RXST) surges 6.1%: Is this an indication of further gains? - MSN
RxSight appoints new CEO - MSN
RXST stock holds as RxSight advances its light-adjustable lens business - Ad-hoc-news.de
BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight - Stock Titan
BTIG Maintains RxSight(RXST.US) With Hold Rating, Announces Target Price $5.25 - Moomoo
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BTIG Maintains RxSight(RXST.US) With Hold Rating, Maintains Target Price $5.25 - Moomoo
RXST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO - VisionMonday.com
RxSight names Aziz Mottiwala as new CEO effective July 20 - Investing.com UK
RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com - Investing.com Australia
RxSIGHT announces significant leadership appointments - Bitget
Ron Kurtz Steps Down as RxSight CEO - Orange County Business Journal
RxSight Names Aziz Mottiwala as CEO - Moomoo
RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package - Stock Titan
Press Release: RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer - Moomoo
RxSight CEO Ron Kurtz to Continue as Chief Medical Officer - Stock Titan
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology - Zacks Investment Research
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs - Ophthalmology Times Europe
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook - MSN
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook - TradingView
RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties - GuruFocus
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - The AI Journal
RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST) - Seeking Alpha
RxSight Inc. (RXST) Holds Near Key Support Amid Slight Decline — Technical Picture in FocusDealer Positioning - dars.gov.et
Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E? - simplywall.st
Is Alcon (SWX:ALC) Undervalued After Its RxSight Collaboration? - Yahoo Finance
Rxsight Inc (RXST) 財務データ
収益
当期純利益
現金流量
EPS
0.79%
4.39%
大文字化:
|
ボリューム (24 時間):